Meeting
2023 ASCO Annual Meeting
Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design.
Authors
Alexander Christopher Jonathan Van Akkooi
Melanoma Institute Australia, Wollstonecraft, Australia
Alexander Christopher Jonathan Van Akkooi , Axel Hauschild , Georgina V. Long , Mario Mandalà , Michal Kicinski , Anne-Sophie Govaerts , Isabelle Klauck , Monia Ouali , Paul Lorigan , Alexander M. Eggermont
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05270044
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9601)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9601
Abstract #
TPS9601
Poster Bd #
359b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).
First Author: Dirk Schadendorf
Poster
2021 Genitourinary Cancers Symposium
Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.
First Author: Andrew James Weickhardt
Poster
2021 Genitourinary Cancers Symposium
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
First Author: Tomasz M. Beer
Poster
2021 Gastrointestinal Cancers Symposium
The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.
First Author: Kohei Shitara